For: | Saif MW. Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer. World J Gastroenterol 2009; 15(31): 3855-3864 [PMID: 19701965 DOI: 10.3748/wjg.15.3855] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v15/i31/3855.htm |
Number | Citing Articles |
1 |
Srinevas K. Reddy, Bryan M. Clary. A New Era in Defining Indications for Resectability of Colorectal Cancer Liver Metastases. Current Colorectal Cancer Reports 2010; 6(2): 89 doi: 10.1007/s11888-010-0049-y
|
2 |
de R. Adam, K. Boudjema, J. Figueiras, L. Gorden, G. Mentha, P. Rougier, F. Kustlinger, G. Piessen, C. Mariette, G. Piessen. Résécabilité secondaire des métastases hépatiques initialement non résécables chez les patients porteurs d’un cancer colorectal : un véritable enjeu !. Journal de Chirurgie Viscérale 2010; 147: S40 doi: 10.1016/S1878-786X(10)70081-4
|
3 |
Hoon Jai Chun, Seun Ja Park, Yun Jeong Lim, Si Young Song. Gastrointestinal Cancer. 2023; : 273 doi: 10.1007/978-981-99-0815-8_39
|
4 |
Hemerson Iury F. Magalhães, Daniel P. Bezerra, Bruno C. Cavalcanti, Diego V. Wilke, Rodrigo Rotta, Dênis P. de Lima, Adilson Beatriz, Ana Paula N. N. Alves, Flávio da S. Bitencourt, Ingrid S. T. de Figueiredo, Nylane M. N. Alencar, Letícia V. Costa-Lotufo, Manoel Odorico Moraes, Claudia Pessoa. In vitro and in vivo antitumor effects of (4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone. Cancer Chemotherapy and Pharmacology 2011; 68(1): 45 doi: 10.1007/s00280-010-1446-2
|
5 |
Theo van Voorthuizen, Thomas M van Gulik, Cornelis JA Punt. Defining resectability of colorectal liver metastases: how and why?. Colorectal Cancer 2013; 2(1): 61 doi: 10.2217/crc.12.79
|
6 |
Ricardo G Amaral, Cecília S Fonseca, Tayane Kayne M Silva, Luciana N Andrade, Maria E França, José M Barbosa-Filho, Damião P de Sousa, Manoel O Moraes, Cláudia Ó Pessoa, Adriana A Carvalho, Sara Maria Thomazzi. Evaluation of the cytotoxic and antitumour effects of the essential oil from Mentha x villosa and its main compound, rotundifolone. Journal of Pharmacy and Pharmacology 2015; 67(8): 1100 doi: 10.1111/jphp.12409
|
7 |
Nir Lubezky, Evan Winograd, Michael Papoulas, Guy Lahat, Einat Shacham-Shmueli, Ravit Geva, Richard Nakache, Joseph Klausner, Menahem Ben-Haim. Perioperative Complications After Neoadjuvant Chemotherapy With and Without Bevacizumab for Colorectal Liver Metastases. Journal of Gastrointestinal Surgery 2013; 17(3): 527 doi: 10.1007/s11605-012-2108-y
|
8 |
István Peták, Richárd Schwab, László Őrfi, László Kopper, György Kéri. Integrating molecular diagnostics into anticancer drug discovery. Nature Reviews Drug Discovery 2010; 9(7): 523 doi: 10.1038/nrd3135
|
9 |
K. Imai, Y. Emi, K.-I. Iyama, T. Beppu, Y. Ogata, Y. Kakeji, H. Samura, E. Oki, Y. Akagi, Y. Maehara, H. Baba. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome. European Journal of Surgical Oncology 2014; 40(5): 559 doi: 10.1016/j.ejso.2013.12.009
|
10 |
Elmar M. Merkle, Christoph J. Zech, Carlo Bartolozzi, Mustafa R. Bashir, Ahmed Ba-Ssalamah, Alexander Huppertz, Jeong Min Lee, Jens Ricke, Michiie Sakamoto, Claude B. Sirlin, Sheng-Long Ye, Mengsu Zeng. Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. European Radiology 2016; 26(3): 674 doi: 10.1007/s00330-015-3873-2
|
11 |
Sébastien Tabariès, Peter M. Siegel. Liver Metastasis: Biology and Clinical Management. Cancer Metastasis - Biology and Treatment 2011; 16: 273 doi: 10.1007/978-94-007-0292-9_10
|
12 |
Jae Hyun Kim, Seun Ja Park. Current Status of Chemotherapy in Colorectal Cancer: Updated Treatment Strategies. The Korean Journal of Gastroenterology 2024; 84(3): 123 doi: 10.4166/kjg.2024.087
|
13 |
Pilar García-Alfonso, Ana Ferrer, Silvia Gil, Rosario Dueñas, María Teresa Pérez, Raquel Molina, Jaume Capdevila, María José Safont, Carmen Castañón, Juana María Cano, Ricardo Lara. Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents. Targeted Oncology 2015; 10(4): 453 doi: 10.1007/s11523-015-0362-0
|
14 |
Marc Peeters. Future directions for selective internal radiation therapy in colorectal cancer. European Journal of Cancer Supplements 2012; 10(3): 15 doi: 10.1016/S1359-6349(12)70034-4
|
15 |
Hüseyin Abalı, Umut Dişel, Yüksel Ürün, İbrahim Güllü, Muhammad Wasif Saif. How Shall We Name the Chemotherapy Administration Before and After Metastasectomy? How About “M-Neoadjuvant” and “M-Adjuvant”?. Annals of Surgical Oncology 2010; 17(7): 1970 doi: 10.1245/s10434-010-1011-6
|
16 |
A. Olivier, C. Baillet, S. Truant, A. Béron, A.-C. Deshorghes, F.-R. Pruvot, D. Huglo. Étude de la variabilité de la clairance hépatique de la mébrofénine-99mTc en scintigraphie hépatobiliaire. Médecine Nucléaire 2013; 37(9): 379 doi: 10.1016/j.mednuc.2013.06.007
|
17 |
Michèle Boisdron-Celle, Jean Philippe Metges, Olivier Capitain, Antoine Adenis, Jean Luc Raoul, Thierry Lecomte, You Heng Lam, Roger Faroux, Claude Masliah, Anne Lise Poirier, Virginie Berger, Alain Morel, Erick Gamelin. A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. Seminars in Oncology 2017; 44(1): 24 doi: 10.1053/j.seminoncol.2017.02.007
|